What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CM313 600mg(4ml)/vial. Subcutaneous injection 1200mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.”In the company’s words, NCT06791772 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma (MM), Primary Immune Thrombocytopenia, Systemic Lupus Erythematosus, IgA Nephropathy, Platelet Transfusion Refractoriness, Aplastic Anemia
- Main trialPhase 3
- “This study consists of two parts. The purpose of Part 1 is to evaluate the safety and tolerability of CM336+CM313 combination therapy in participants with relapsed or refractory multiple myeloma (RRMM). Part 2 is to compare the efficacy of CM336 + CM313 (Group A) with Daratumumab + Pomalidomide +Dexamethasone (DPd) (Group B) in RRMM patients.”In the company’s words, NCT07910903 on ClinicalTrials.gov
Other drugs for Multiple Myeloma (MM)
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up4
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
- 16 Nov 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- May 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | May 2030 | Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma | |
| Phase 2Active, not recruiting | 30 Dec 2025 | Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) | |
| Phase 2Not yet recruiting | Oct 2026 | Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE) | |
| Phase 2Not yet recruiting | Mar 2027 | Study of CM313 in Subject With IgA Nephropathy | |
| Phase 1/2Recruiting | 16 Nov 2027 | Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness | |
| Phase 1/2Not yet recruiting | Dec 2027 | Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia | |
| Phase 1/2Unknown | 30 Oct 2023 | A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus | |
| Phase 1/2Unknown | 28 Feb 2026 | A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma | |
| Phase 1Unknown | Jan 2023 | Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma | |
| Phase 1Unknown | 30 Apr 2025 | Study of CM313 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026